GLP1R and inflammatory bowel disease: An additional element of relevance when treating patients with IBD is the infectious risk associated with GLP-1 RAs, as these patients often undergo concomitant advanced treatment with biological agents and small molecules, which carry a specific infectious risk that must be considered [72].